Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06448780
PHASE1

Dose Optimization of Caffeine for HIE

Sponsor: University of North Carolina, Chapel Hill

View on ClinicalTrials.gov

Summary

This is a phase Ib, open-label, dose-validating and safety study of caffeine in neonates with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia.

Official title: Dose Optimization of Caffeine in Neonates With Hypoxic-Ischemic Encephalopathy

Key Details

Gender

All

Age Range

Any - 24 Hours

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2024-07-26

Completion Date

2028-11

Last Updated

2026-04-07

Healthy Volunteers

No

Interventions

DRUG

Caffeine citrate 20 mg/kg

Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.

DRUG

Caffeine citrate 30 mg/kg

Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.

Locations (2)

The University of North Carolina at Chapel Hill Newborn Critical Care Center

Chapel Hill, North Carolina, United States

Novant Health New Hanover Regional Medical Center

Wilmington, North Carolina, United States